These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32990630)

  • 1. Promoting Safe Injection Practices, Substance Use Reduction, Hepatitis C Testing, and Overdose Prevention Among Syringe Service Program Clients Using a Computer-Tailored Intervention: Pilot Randomized Controlled Trial.
    Hochstatter KR; Hull SJ; Sethi AK; Burns ME; Mundt MP; Westergaard RP
    J Med Internet Res; 2020 Sep; 22(9):e19703. PubMed ID: 32990630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computerized Tailored Interventions to Enhance Prevention and Screening for Hepatitis C Virus Among People Who Inject Drugs: Protocol for a Randomized Pilot Study.
    Westergaard RP; Hull SJ; Merkow A; Stephens LK; Hochstatter KR; Olson-Streed HK; Baker LM; Hess TM
    JMIR Res Protoc; 2016 Jan; 5(1):e15. PubMed ID: 26800903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
    Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
    Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access to HIV, Viral Hepatitis, and Substance Use Disorder Treatment/Overdose Prevention Services: A Qualitative Analysis of Syringe Service Programs (SSPs) Serving Rural PWID.
    Carnes NA; Asher AK; Bohm MK; Bessler PA
    Subst Use Misuse; 2021; 56(13):1933-1940. PubMed ID: 34353216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of an mHealth Intervention on Hepatitis C Testing Uptake Among People With Opioid Use Disorder: Randomized Controlled Trial.
    Hochstatter KR; Gustafson DH; Landucci G; Pe-Romashko K; Cody O; Maus A; Shah DV; Westergaard RP
    JMIR Mhealth Uhealth; 2021 Feb; 9(2):e23080. PubMed ID: 33616545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV serostatus and injection sharing practices among those who obtain syringes from pharmacies and directly and indirectly from syringe services programs in rural New England.
    Romo E; Rudolph AE; Stopka TJ; Wang B; Jesdale BM; Friedmann PD
    Addict Sci Clin Pract; 2023 Jan; 18(1):2. PubMed ID: 36597153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peer Intervention to Link Overdose Survivors to Treatment (PILOT): Protocol for a Multisite, Randomized Controlled Trial Conducted Within the National Institute on Drug Abuse Clinical Trials Network.
    Papa C; McClure EA; McCauley J; Haynes L; Matheson T; Jones R; Jennings L; Lawdahl T; Ward R; Brady K; Barth KS
    JMIR Res Protoc; 2024 Sep; 13():e60277. PubMed ID: 39288373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Mobile Health Intervention to Improve Hepatitis C Outcomes Among People With Opioid Use Disorder: Protocol for a Randomized Controlled Trial.
    Hochstatter KR; Gustafson DH; Landucci G; Pe-Romashko K; Maus A; Shah DV; Taylor QA; Gill EK; Miller R; Krechel S; Westergaard RP
    JMIR Res Protoc; 2019 Aug; 8(8):e12620. PubMed ID: 31373273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential risks of syringe service program participants in Central Ohio: a latent class analysis.
    Moon KJ; Bryant I; Trinh A; Hasenstab KA; Carter B; Barclay R; Nawaz S
    Harm Reduct J; 2023 Jul; 20(1):97. PubMed ID: 37507721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in injection risk behaviors after implementation of a syringe services program, Miami, Florida.
    Bartholomew TS; Feaster DJ; Patel H; Forrest DW; Tookes HE
    J Subst Abuse Treat; 2021 Aug; 127():108344. PubMed ID: 34134863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial differences in overdose training, naloxone possession, and naloxone administration among clients and nonclients of a syringe services program.
    Jones AA; Park JN; Allen ST; Schneider KE; Weir BW; Hunt D; Sherman SG
    J Subst Abuse Treat; 2021 Oct; 129():108412. PubMed ID: 34080560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescription opioid injection among young people who inject drugs in New York City: a mixed-methods description and associations with hepatitis C virus infection and overdose.
    Mateu-Gelabert P; Guarino H; Zibbell JE; Teubl J; Fong C; Goodbody E; Edlin B; Salvati C; Friedman SR
    Harm Reduct J; 2020 Mar; 17(1):22. PubMed ID: 32228700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary Efficacy of a Theory-Informed Intervention to Increase COVID-19 Testing Uptake Among People Who Inject Drugs in San Diego County: Findings From a Pilot Randomized Controlled Trial.
    Bazzi AR; Abramovitz D; Harvey-Vera A; Stamos-Buesig T; Vera CF; Artamonova I; Logan J; Patterson TL; Strathdee SA
    Ann Behav Med; 2023 May; 57(6):472-482. PubMed ID: 37029714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study.
    Barocas JA; Brennan MB; Hull SJ; Stokes S; Fangman JJ; Westergaard RP
    Harm Reduct J; 2014 Jan; 11():1. PubMed ID: 24422784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injecting Alone: Practices and Preferences among People Who Inject Drugs in New York City.
    Riback L; Pérez-Correa AE; Ghiroli MM; López-Castro T; Fox AD
    Subst Use Misuse; 2022; 57(13):1988-1996. PubMed ID: 36151968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study.
    Roux P; Rojas Castro D; Ndiaye K; Debrus M; Protopopescu C; Le Gall JM; Haas A; Mora M; Spire B; Suzan-Monti M; Carrieri P
    PLoS One; 2016; 11(6):e0157062. PubMed ID: 27294271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Young Drug Users: a Vulnerable Population and an Underutilized Resource in HIV/HCV Prevention.
    Mateu-Gelabert P; Guarino H; Quinn K; Meylakhs P; Campos S; Meylakhs A; Berbesi D; Toro-Tobón D; Goodbody E; Ompad DC; Friedman SR
    Curr HIV/AIDS Rep; 2018 Aug; 15(4):324-335. PubMed ID: 29931468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
    Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
    J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.